ATE459350T1 - Behandlung von schwerer aphasie bei chronischen zerebrovaskulären erkrankungen - Google Patents

Behandlung von schwerer aphasie bei chronischen zerebrovaskulären erkrankungen

Info

Publication number
ATE459350T1
ATE459350T1 AT04807730T AT04807730T ATE459350T1 AT E459350 T1 ATE459350 T1 AT E459350T1 AT 04807730 T AT04807730 T AT 04807730T AT 04807730 T AT04807730 T AT 04807730T AT E459350 T1 ATE459350 T1 AT E459350T1
Authority
AT
Austria
Prior art keywords
treatment
cerebrovascular diseases
chronic cerebrovascular
severe aphasia
aphasia
Prior art date
Application number
AT04807730T
Other languages
English (en)
Inventor
Hideki Ohyama
Original Assignee
Hideki Ohyama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hideki Ohyama filed Critical Hideki Ohyama
Application granted granted Critical
Publication of ATE459350T1 publication Critical patent/ATE459350T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
AT04807730T 2003-12-24 2004-12-24 Behandlung von schwerer aphasie bei chronischen zerebrovaskulären erkrankungen ATE459350T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003427424 2003-12-24
PCT/JP2004/019373 WO2005061454A1 (ja) 2003-12-24 2004-12-24 脳血管障害慢性期の重度失語症に対する治療剤又は治療方法

Publications (1)

Publication Number Publication Date
ATE459350T1 true ATE459350T1 (de) 2010-03-15

Family

ID=34708892

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04807730T ATE459350T1 (de) 2003-12-24 2004-12-24 Behandlung von schwerer aphasie bei chronischen zerebrovaskulären erkrankungen

Country Status (6)

Country Link
EP (1) EP1698622B1 (de)
JP (1) JPWO2005061454A1 (de)
AT (1) ATE459350T1 (de)
DE (1) DE602004025849D1 (de)
ES (1) ES2340040T3 (de)
WO (1) WO2005061454A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2380111C2 (ru) * 2007-07-13 2010-01-27 Государственное учреждение "Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева" (НИПИ им. В.М. Бехтерева) Способ лечения афазий
LV14346B (lv) * 2009-11-05 2011-07-20 Grindeks, A/S 2-(4-Fenil-5-metil-2-oksopirolidin-1-il)-acetamīda 4R,5S-enantiomērs ar nootropo aktivitāti

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2440634A1 (de) * 1974-08-24 1976-03-04 Chemisches Lab Fritzwalter Lan Verfahren zur herstellung von (2-oxopyrrolidin-1)-acetamid
RU2145895C1 (ru) * 1996-12-24 2000-02-27 Главный военный клинический госпиталь им.акад.Н.Н.Бурденко Способ лечения церебрального ишемического инсульта

Also Published As

Publication number Publication date
EP1698622A4 (de) 2007-08-08
EP1698622A1 (de) 2006-09-06
WO2005061454A1 (ja) 2005-07-07
DE602004025849D1 (de) 2010-04-15
JPWO2005061454A1 (ja) 2007-07-12
ES2340040T3 (es) 2010-05-28
EP1698622B1 (de) 2010-03-03

Similar Documents

Publication Publication Date Title
BRPI0413234A (pt) derivados de imidazola bicìclica contra flaviviridae
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
BR0307058A (pt) N-óxidos de derivados de n-fenil-2-pirimidina-amina
EP1551812A4 (de) Mitotische kinesinhemmer
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
EP1481077A4 (de) Mitotische kinesin-hemmer
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
ATE480255T1 (de) Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
EP1626730A4 (de) Verfahren, gerät und zusammensetzung zur behandlung von akne
ATE458485T1 (de) Ubiquitin-ligase-hemmer und verwandte verfahren
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DE60103171D1 (de) Verfahren und verbindungen zur behandlung proliferativer erkrankungen
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
ATE497763T1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
ATE462702T1 (de) Für die behandlung von entzündlichen krankheiten nützliche beta-carboline
ATE423110T1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
ATE359816T1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
ATE495735T1 (de) Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden
ATE459350T1 (de) Behandlung von schwerer aphasie bei chronischen zerebrovaskulären erkrankungen
ATE426605T1 (de) Inhibitoren von mitotischem kinesin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties